Vaxxinity, Inc. (VAXX): Price and Financial Metrics
VAXX Price/Volume Stats
Current price | $0.00 | 52-week high | $1.31 |
Prev. close | $0.00 | 52-week low | $0.00 |
Day low | $0.00 | Volume | 1,600 |
Day high | $0.00 | Avg. volume | 775,538 |
50-day MA | $0.02 | Dividend yield | N/A |
200-day MA | $0.25 | Market Cap | 25.35K |
VAXX Stock Price Chart Interactive Chart >
Vaxxinity, Inc. (VAXX) Company Bio
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.
VAXX Price Returns
1-mo | 0.00% |
3-mo | 0.00% |
6-mo | 0.00% |
1-year | 0.00% |
3-year | 0.00% |
5-year | N/A |
YTD | 0.00% |
2023 | -39.29% |
2022 | -75.04% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...